ResearcherHarvard UniversityActive in the last 2 years
ANDREA C Enzinger
Matched on ORCID iD 0000-0001-7502-8081; OpenAlex author ID A5059793697, A5109058637; NIH RePORTER profile ID 10748651. Sources: ClinicalTrials.gov.
Their work
- Papers
- 3
- Trials
- 2 (principal investigator on 2)
- Grants
- 1
- Labs led
- 1
- Collaborators
- 37
2015: 1 trial · 2016: none · 2017: none · 2018: 1 trial · 2019: none · 2020: 1 grant · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 2 papers
Papers 3
- Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Co-author DOI 10.1038/s43018-026-01165-8↗
- A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Co-author DOI 10.1158/1078-0432.ccr-24-3766↗
- Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
Trials 2
- EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options Principal investigator NCT03602885↗
- Improving Informed Consent for Palliative Chemotherapy Principal investigator NCT02282722↗
Grants 1
Closest collaborators
The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Harshabad Singh · 3 shared papers, 2025–2026 · strength 0.52
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Douglas Adam Rubinson · 3 shared papers, 2025–2026 · strength 0.52
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Srivatsan Raghavan · 3 shared papers, 2025–2026 · strength 0.52
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Kimmie Ng · 3 shared papers, 2025–2026 · strength 0.52
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Andrew J. Aguirre · 3 shared papers, 2025–2026 · strength 0.52
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Brian Matthew Wolpin · 3 shared papers, 2025–2026 · strength 0.52
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Jonathan Andrew Nowak · 3 shared papers, 2025–2026 · strength 0.52
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Kimberly J. Perez · 3 shared papers, 2025–2026 · strength 0.52
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- James M. Cleary · 3 shared papers, 2025–2026 · strength 0.52
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Mary Linton B. Peters · 2 shared papers, 2025–2026 · strength 0.34
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Andrea J. Bullock · 2 shared papers, 2025–2026 · strength 0.34
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Leah H. Biller · 2 shared papers, 2025–2026 · strength 0.34
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Matthew B.B. Yurgelun · 2 shared papers, 2025–2026 · strength 0.34
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Brandon M. Huffman · 2 shared papers, 2025–2026 · strength 0.34
- Paper A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, … DOI 10.1158/1078-0432.ccr-24-3766↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Rishi Surana · 2 shared papers, 2025–2026 · strength 0.33
- Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Thomas Adam Abrams · 2 shared papers, 2025–2026 · strength 0.33
- Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Nadine A. Jackson · 1 shared paper, 2026 · strength 0.19
- Alan D. D’Andrea · 1 shared paper, 2026 · strength 0.19
- Geoffrey Ira Shapiro · 1 shared paper, 2026 · strength 0.19
- Peter James O'Dwyer · 1 shared paper, 2026 · strength 0.18
- Thomas Benjamin Karasic · 1 shared paper, 2026 · strength 0.18
- Jennifer Susan Thalappillil · 1 shared paper, 2026 · strength 0.18
- C. Sloane Furniss · 1 shared paper, 2026 · strength 0.18
- Andressa Dias Costa · 1 shared paper, 2026 · strength 0.18
- Jen Jen Yeh · 1 shared paper, 2026 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.